IL15 and neuroblastoma: The first phase I clinical trial for the treatment of relapsed or refractory NB patients using autologous NKTs co-expressing a GD2-specific CAR with interleukin 15 (IL15) (GD2-CAR.15) is ongoing (NCT03294954).